Extracellular vesicles in atherosclerotic cardiovascular disease: mechanisms and therapeutic implications
Listen to this summary
The authors investigate the role of extracellular vesicles (EVs) in the mechanisms underlying atherosclerotic cardiovascular disease and their potential as therapeutic targets. They highlight how EVs from various cell types contribute to inflammation, plaque formation, and instability in atherosclerosis, suggesting that manipulating EVs could provide new strategies for monitoring and treating this condition. The study emphasizes the need for further exploration of EVs as biomarkers and therapeutic agents in atherosclerosis management.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.
More from European heart journal
View all →Jun 11, 2026 · European heart journal
Accelerated epigenetic ageing in congenital heart disease: the AccelerAGE study
Jun 9, 2026 · European heart journal
Statins and survival free of incident frailty among older US veterans
Jun 5, 2026 · European heart journal
Predicting lifetime cardiovascular risk and benefits of preventive treatment in patients with established atherosclerotic cardiovascular disease: the SMART-REACH2 model
Jun 5, 2026 · European heart journal
P2Y12 inhibitor monotherapy after abbreviated dual antiplatelet therapy following percutaneous coronary intervention: a meta-analysis
Jun 5, 2026 · European heart journal
ACADM-mediated fatty acid β-oxidation pathway in atherosclerosis and abdominal aortic aneurysm
Jun 5, 2026 · European heart journal
RNA splicing and cardiovascular disease: a guide for cardiologists
More in Internal Medicine
View all →Jun 25, 2026 · Blood
Combining Quizartinib with intensive chemotherapy in older patients with newly diagnosed AML: results of the UK NCRI AML18 Trial
Jun 25, 2026 · Blood
Translational Regulation of Sf1 Integrates Alternative Splicing and Hematopoietic Stem Cell Fate
Jun 25, 2026 · Blood
Galectin-1 Fuels Monocyte Hyperinflammation and Represents a Novel Therapeutic Target in Myeloproliferative Neoplasms
Jun 25, 2026 · The American journal of sports medicine
Association of Central Acetabular Osteophytes With Microinstability and Increased Combined Anteversion in Borderline Dysplasia Hips
Jun 25, 2026 · Blood
NG2-ITGA4 axis regulates Rho GTPases and leukemic aggressiveness in KMT2A-r B-ALL and is targetable with natalizumab
Jun 24, 2026 · Lancet (London, England)
Safety, pharmacokinetics, and exploratory efficacy of the oral ghrelin receptor agonist AC01 in heart failure with reduced ejection fraction (GOAL-HF1): a randomised, double-blind, placebo-controlled, phase 1b/2a study
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR
Stay current without falling behind
33,000+ journals. 3-minute audio summaries. Free for 14 days.
